IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, June 2026
Impact Factor: 8.2

Formulation and Evaluation of Caffeine Topical Stick for Migraine: A Review

Miss. Sayli Kote[1]* and Mr. Ratnaparkhe. R. R[2]
[1]Student, Rashtrasant Janardhan Swami College of Pharmacy, Kokamthan, Kopargaon, Maharashtra, India.
[2]Assistant Professor, Rashtrasant Janardhan Swami College of Pharmacy, Kokamthan, Kopargaon, Maharashtra, India.
Corresponding Author: Miss. Sayli Kote
balpanderenuka3@gmail.com

Abstract: *Migraine is a chronic neurovascular disorder characterized by recurrent episodes of severe headache accompanied by nausea, vomiting, photophobia, and phonophobia. It affects millions of people worldwide and significantly impacts quality of life. Caffeine is widely used as an adjuvant in migraine treatment because of its vasoconstrictive properties and ability to enhance the efficacy of analgesics. Conventional oral administration of caffeine may be associated with gastrointestinal disturbances and delayed absorption during migraine attacks. Therefore, topical delivery systems have emerged as promising alternatives. Topical sticks offer advantages such as ease of application, portability, improved patient compliance, controlled drug release, and avoidance of first-pass metabolism. This review discusses the pathophysiology of migraine, the pharmacological role of caffeine, formulation aspects of caffeine topical sticks, evaluation parameters, advantages, challenges, and future perspectives.*

Keywords: Migraine, Caffeine, Topical Stick, Transdermal Drug Delivery, Formulation, Evaluation.

I. INTRODUCTION

Migraine is one of the most common neurological disorders and affects approximately 15% of the global population. It is characterized by recurrent attacks of moderate to severe headache that may last from 4 to 72 hours. Associated symptoms include nausea, vomiting, sensitivity to light, and sensitivity to sound [1]. Migraine is considered a neurovascular disorder involving activation of the trigeminovascular system, neurogenic inflammation, and changes in cerebral blood flow [2].

Current migraine management includes analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), triptans, ergot alkaloids, and adjuvant therapies. Among these, caffeine has been extensively utilized either alone or in combination with analgesics because of its ability to improve therapeutic efficacy [3].

The oral route remains the most common mode of administration; however, oral drug absorption may be compromised during migraine attacks due to delayed gastric emptying and nausea. Consequently, topical and transdermal drug delivery systems have gained considerable attention as alternative routes of administration [4]. Topical sticks represent a convenient and patient-friendly dosage form capable of delivering active ingredients through the skin while providing prolonged contact and controlled release.

II. MIGRAINE: PATHOPHYSIOLOGY AND CLINICAL FEATURES

Migraine is a complex neurological condition involving genetic, vascular, and neurochemical factors. The exact mechanism is not fully understood, but several theories have been proposed.

2.1 Trigeminovascular Theory

The trigeminovascular system plays a critical role in migraine pathogenesis. Activation of trigeminal nerve fibers leads to the release of neuropeptides such as calcitonin gene-related peptide (CGRP), substance P, and neurokinin A. These mediators produce vasodilation, inflammation, and pain transmission [5].

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, June 2026
Impact Factor: 8.2

2.2 Vascular Changes

Migraine attacks are associated with alterations in cerebral blood vessel diameter. Initial vasoconstriction may be followed by vasodilation, contributing to headache symptoms [6].

2.3 Role of Adenosine

Adenosine concentrations increase during migraine attacks. Elevated adenosine levels contribute to vasodilation and pain perception. Therefore, agents that antagonize adenosine receptors, such as caffeine, may provide therapeutic benefits [7].

III. PHARMACOLOGICAL ROLE OF CAFFEINE IN MIGRAINE

Caffeine (1,3,7-trimethylxanthine) is a naturally occurring methylxanthine alkaloid found in coffee, tea, cocoa, and various beverages. It possesses central nervous system stimulant activity and has been widely used in headache management [8].

3.1 Mechanism of Action

Adenosine Receptor Antagonism

Caffeine acts as a competitive antagonist of adenosine A1 and A2A receptors. By blocking these receptors, caffeine prevents adenosine-induced vasodilation and reduces pain signaling [9].

Cerebral Vasoconstriction

Caffeine induces constriction of cerebral blood vessels, thereby reducing vascular distension associated with migraine headaches [10].

Enhancement of Analgesic Activity

Studies have demonstrated that caffeine enhances the efficacy of analgesic drugs such as paracetamol, aspirin, and ibuprofen. The addition of caffeine can improve pain relief by approximately 40% compared with analgesics alone [11].

IV. RATIONALE FOR TOPICAL DELIVERY OF CAFFEINE

The oral route presents several challenges during migraine attacks.

Limitations of Oral Therapy

- Delayed gastric emptying
- Nausea and vomiting
- Variable drug absorption
- Gastrointestinal irritation
- First-pass hepatic metabolism [12]

Advantages of Topical Delivery

- Bypasses gastrointestinal tract
- Avoids first-pass metabolism
- Sustained drug release
- Improved patient compliance
- Reduced systemic adverse effects
- Easy administration during migraine attacks [13]

These advantages support the development of caffeine topical sticks as an alternative dosage form.

V. TOPICAL STICK DRUG DELIVERY SYSTEM

Topical sticks are semisolid dosage forms prepared using waxes, oils, and active pharmaceutical ingredients. They remain solid at room temperature but soften upon skin contact, facilitating drug application.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, June 2026
Impact Factor: 8.2

Advantages

- Portable and convenient
- Non-greasy
- Accurate dosing
- Enhanced stability
- Easy storage and transportation
- Better patient acceptability [14]

VI. FORMULATION OF CAFFEINE TOPICAL STICK

6.1 Active Pharmaceutical Ingredient

Caffeine

Caffeine serves as the primary therapeutic agent. It should be uniformly dispersed within the formulation to ensure consistent drug release and efficacy.

Typical concentration: 1–5% w/w [15].

6.2 Waxes

Waxes provide rigidity and structural integrity.

Examples:

Beeswax

Carnauba wax

Paraffin wax

Candelilla wax [16]

6.3 Emollients

Emollients improve texture, skin feel, and spreadability.

Examples:

Cetyl alcohol

Stearyl alcohol

Cocoa butter

Lanolin [17]

6.4 Penetration Enhancers

The stratum corneum acts as a major barrier to drug permeation. Penetration enhancers improve caffeine transport through the skin.

Examples:

Propylene glycol

Ethanol

Oleic acid

Isopropyl myristate

Transcutol® [18]

6.5 Preservatives

Preservatives prevent microbial growth.

Examples:

Methyl paraben

Propyl paraben [19]

6.6 Antioxidants

Antioxidants protect formulation components from oxidation.

Examples:

BHT

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, June 2026
Impact Factor: 8.2

BHA
Tocopherol [20]

6.7 Cooling Agents

Cooling agents provide immediate soothing effects.
Examples:
Menthol
Peppermint oil
Eucalyptus oil [21]

VII. METHOD OF PREPARATION

The fusion method is commonly employed.

Procedure

Accurately weigh all ingredients.
Melt waxes in a water bath.
Add emollients and penetration enhancers.
Dissolve caffeine in a suitable solvent.
Incorporate caffeine solution into molten base.
Add preservatives and antioxidants.
Mix thoroughly until homogeneous.
Pour into stick molds.
Allow cooling and solidification.
Package appropriately [22].

VIII. EVALUATION OF CAFFEINE TOPICAL STICK

8.1 Physical Appearance

The formulation should be evaluated for:
Color
Odor
Surface smoothness
Homogeneity
Presence of cracks [23]

8.2 pH Determination

The pH should be compatible with skin physiology.
Ideal range: 5.0–7.0 [24]

8.3 Weight Variation Test

Uniformity of weight ensures consistent dosing.

Formula

Weight Variation (%) =
(Individual Weight − Average Weight) ÷ Average Weight × 100

8.4 Drug Content Uniformity

This test determines the uniform distribution of caffeine throughout the formulation.
Acceptable range: 85–115% of labeled amount [25].

8.5 Hardness Test

Hardness determines mechanical strength and resistance to breakage during handling [26].

8.6 Spreadability

Spreadability influences ease of application.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, June 2026
Impact Factor: 8.2

Formula

S = M × L / T

Where:

S = Spreadability

M = Weight tied to upper slide

L = Length moved

T = Time taken [27]

8.7 Extrudability

Measures ease of product application from the container [28].

8.8 In Vitro Drug Release Study

Drug release studies are performed using Franz diffusion cells.

Parameters measured:

Drug release rate

Cumulative drug release

Release kinetics [29]

8.9 Ex Vivo Skin Permeation Study

Animal or porcine skin is used to determine:

Flux

Permeability coefficient

Drug retention [30]

8.10 Skin Irritation Study

The formulation should be tested for:

Erythema

Edema

Allergic reactions [31]

8.11 Stability Studies

Stability testing is performed according to ICH guidelines.

Conditions:

25 ± 2°C / 60 ± 5% RH

40 ± 2°C / 75 ± 5% RH

Parameters monitored:

Appearance

Drug content

Hardness

Release profile [32]

IX. CHALLENGES IN FORMULATION DEVELOPMENT

Several challenges are associated with caffeine topical sticks.

Poor skin permeability of caffeine

Barrier properties of stratum corneum

Limited drug loading

Formulation instability

Optimization of penetration enhancers [33]

Novel approaches such as nanoemulsions, lipid nanoparticles, and proniosomes are being explored to overcome these limitations.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, June 2026
Impact Factor: 8.2

X. FUTURE PERSPECTIVES

Future research should focus on:
Nanoemulsion-based topical sticks
Nanostructured lipid carriers
Proniosomal caffeine delivery systems
Combination products containing caffeine and menthol
Clinical trials in migraine patients
Personalized transdermal therapy [34]
These advances may improve therapeutic outcomes and patient compliance.

XI. CONCLUSION

Caffeine topical sticks represent a promising alternative approach for migraine management. The formulation offers several advantages, including avoidance of gastrointestinal complications, bypassing first-pass metabolism, ease of administration, and sustained drug delivery. Proper selection of waxes, penetration enhancers, and stabilizers is essential for achieving optimal performance. Evaluation studies such as drug content determination, permeability assessment, stability testing, and skin irritation studies are critical for ensuring product quality and efficacy. With continued advancements in transdermal drug delivery technologies, caffeine topical sticks may emerge as an effective and patient-friendly dosage form for migraine treatment.

REFERENCES

[1] Steiner TJ, Stovner LJ, Vos T. J Headache Pain. 2018;19:17.
[2] Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Physiol Rev. 2017;97:553-622.
[3] Lipton RB, Diener HC, Robbins MS, Garas SY, Patel K. J Headache Pain. 2017;18:107.
[4] Aurora SK, Kori SH, Barrodale PM, McDonald SA, Haseley D. Headache. 2006;46:57-63.
[5] Edvinsson L. Nat Rev Neurol. 2019;15:338-350.
[6] Moskowitz MA. Neurology. 1993;43:S16-S20.
[7] Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Pharmacol Rev. 1999;51:83-133.
[8] Nehlig A. Brain Res Rev. 1992;17:139-170.
[9] Fredholm BB. Handb Exp Pharmacol. 2011;200:201-220.
[10] Addicott MA, Yang LL, Peiffer AM. Hum Brain Mapp. 2009;30:3102-3114.
[11] Derry CJ, Derry S, Moore RA. Cochrane Database Syst Rev. 2014;12:CD009281.
[12] Aurora SK. Headache. 2013;53:1230-1244.
[13] Prausnitz MR, Langer R. Nat Biotechnol. 2008;26:1261-1268.
[14] Barry BW. Dermatological Formulations. Marcel Dekker; 1983.
[15] Luo L, Lane ME. Int J Pharm. 2015;490:155-164.
[16] Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 8th ed.
[17] Aulton ME. Aulton's Pharmaceutics. 6th ed.
[18] Williams AC, Barry BW. Adv Drug Deliv Rev. 2012;64:128-137.
[19] Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy.
[20] Allen LV. Remington: The Science and Practice of Pharmacy. 23rd ed.
[21] Eccleston GM. Pharmaceutics: The Science of Dosage Form Design.
[22] Ansel HC. Pharmaceutical Dosage Forms and Drug Delivery Systems.
[23] Indian Pharmacopoeia. General Monographs.
[24] USP-NF. United States Pharmacopeia.
[25] ICH Q6A Specifications.

DOI: 10.48175/568

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, June 2026
Impact Factor: 8.2

[26] Banker GS, Rhodes CT. Modern Pharmaceutics.
[27] Mutimer MN. J Pharm Sci. 1956;45:212-218.
[28] Garg A, Aggarwal D, Garg S. Pharm Technol. 2002;26:84-105.
[29] Franz TJ. J Invest Dermatol. 1975;64:190-195.
[30] Hadgraft J, Lane ME. Int J Pharm. 2005;305:2-12.
[31] OECD Guideline 404 for Skin Irritation Testing.
[32] ICH Q1A(R2): Stability Testing Guidelines.
[33] Benson HAE. Curr Drug Deliv. 2005;2:23-33.
[34] Abdellatif AAH, Tawfeek HM. Process Biochemistry. 2020;97:201-212.